Lexicon Pharmaceuticals, Inc. (LXRX)

NASDAQ: LXRX · IEX Real-Time Price · USD

1.650

+0.020 (1.23%)

At close: Apr 19, 2024, 4:00 PM

1.690

+0.040 (2.42%)

After-hours: Apr 19, 2024, 7:53 PM EDT

Lexicon Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1997
Net Income	-177.12	-101.94	-87.76	-58.57	130.13	-120.55	-122.99	-131.45	-4.68	-100.29	Upgrade
Depreciation & Amortization	0.55	0.43	0.29	2.93	3.65	3.68	3.4	2.06	0.73	1.93	Upgrade
Share-Based Compensation	14.34	11.52	10.58	13.27	14.22	11.7	9.47	7.45	6.84	7.08	Upgrade
Other Operating Activities	0.33	1.15	-10.13	-100.6	-34.2	-43.44	-75.27	-53.69	181.89	15.66	Upgrade
Operating Cash Flow	-161.9	-88.85	-87.02	-142.97	113.81	-148.61	-185.39	-175.63	184.78	-75.62	Upgrade
Capital Expenditures	-0.47	-1.33	-1.22	10.93	-0.07	-0.1	-0.23	-0.23	-0.58	2.09	Upgrade
Acquisitions	0	0	0	160.39	0	0	0	0	0	0	Upgrade
Change in Investments	-49.47	-69.75	3.33	209.45	-155.79	169.67	50.75	18.48	-116.45	-110.51	Upgrade
Investing Cash Flow	-49.94	-71.08	2.11	380.76	-155.86	169.58	50.52	18.25	-117.02	-108.42	Upgrade
Share Issuance / Repurchase	138	93.34	34.41	68.94	-0.94	-0.24	6.31	3	-0.24	201.38	Upgrade
Debt Issued / Paid	49.96	48.87	-11.7	-216.58	-1.29	-2	143.63	-2.02	-1.86	82.43	Upgrade
Other Financing Activities	-	-	-	-	-	-	-	-	0.07	-	Upgrade
Financing Cash Flow	187.96	142.21	22.71	-147.64	-2.23	-2.24	149.93	0.99	-2.03	283.81	Upgrade
Net Cash Flow	-23.88	-17.72	-62.2	90.15	-44.27	18.73	15.06	-156.39	65.72	99.77	Upgrade
Free Cash Flow	-162.37	-90.18	-88.24	-132.04	113.74	-148.7	-185.62	-175.86	184.2	-73.53	Upgrade
Free Cash Flow Margin	-13485.63%	-64875.54%	-29610.07%	-550.29%	35.31%	-235.25%	-202.45%	-221.89%	141.68%	-321.75%	Upgrade
Free Cash Flow Per Share	-0.73	-0.54	-0.61	-1.19	1.07	-1.41	-1.76	-1.69	1.78	-0.96	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).